Long-term follow-up of patients treated with daclizumab for steroid-refractory acute graft-vs-host disease

Ma, Perales; Ishill, Nicole; Wa, Lomazow; Dm, Weinstock; Papadopoulos, E.; Dastigir, H.; Chiu, Michelle; Boulad, Farid; Hr, Castro-Malaspina; Heller, Glenn; Aa, Jakubowski; O’Reilly, RJ; Small, Tania; Young, James W.; Kernan, Nancy A.

doi:10.1038/sj.bmt.1705762

Cited by 71 publications

(55 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…These results confirm the higher response rate that was observed earlier in a paediatric series as compared with the series involving exclusively adult populations. 5,8,9 As far as organ involvement is concerned, all of our patients with cutaneous aGVHD responded to therapy, regardless of the grade of the disease. This result is in agreement with previous series that demonstrated the efficacy of Dac on this district.…”

Section: Discussionmentioning

confidence: 79%

“…11,12 Dac was also found to be effective as second-line treatment of steroid-resistant GVHD in a limited number of reports that mostly referred to adult populations. [5][6][7][8][9][10] Response rates for aGVHD ranged between 29 and 68% in these series; however, data regarding the children who were included in these studies were not evaluable separately because they were not stratified by age. The only study on an exclusively paediatric population showed the safety and efficacy of Dac in treating both acute and chronic cutaneous GVHD.…”

Section: Discussionmentioning

confidence: 99%

“…This is in line with the evidence that Dac may be more effective in early stages of aGVHD. 9 The liver appears to be the least responsive organ, with only one patient achieving CR.…”

Section: Discussionmentioning

confidence: 99%

“…In studies involving exclusively adults, or both adult and paediatric populations, [5][6][7][8][9][10] Dac is reportedly safe when used in children as rejection prophylaxis after organ transplantation, 11,12 and effective in the second-line treatment of refractory acute GVHD (aGVHD) and chronic GVHD (cGVHD).…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Daclizumab as useful treatment in refractory acute GVHD: a paediatric experience

Miano

Cuzzubbo

Terranova

et al. 2008

Bone Marrow Transplant

View full text Add to dashboard Cite

GVHD remains a serious complication after allogeneic SCT. We describe 13 paediatric patients treated with daclizumab for refractory acute GVHD (aGVHD). After 30 days of daclizumab administration, all patients with cutaneous aGVHD reached complete response. Among patients with gastrointestinal disease, 50 and 30% had complete and partial response, respectively, whereas 11 and 55% of patients with hepatic aGVHD achieved CR and PR, respectively. Overall, complete (46%) and partial (46%) responses were demonstrated in 92% of our patients, whereas the remaining patients (8%) were nonresponders. No life-threatening infectious episodes were recorded within 100 days from transplant in this selected group of paediatric patients. Overall 46% of patients were alive at a median of 461 days from SCT, but 50% of them developed chronic GVHD. In our experience, daclizumab proved to be a useful and safe treatment for refractory and steroid-resistant/dependent aGVHD, in particular for cutaneous and low-moderate intestinal involvement.

show abstract

Section: Discussionmentioning

confidence: 79%

Section: Discussionmentioning

confidence: 99%

“…This is in line with the evidence that Dac may be more effective in early stages of aGVHD. 9 The liver appears to be the least responsive organ, with only one patient achieving CR.…”

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Daclizumab as useful treatment in refractory acute GVHD: a paediatric experience

Miano

Cuzzubbo

Terranova

et al. 2008

Bone Marrow Transplant

View full text Add to dashboard Cite

show abstract

“…This observation differs from the finding in bone marrow transplant recipients which reported a 95% incidence of opportunistic infections. 28 The use of steroids, as well as the fact that these patients had undergone transplantation (all but one was myeloablative), many from mismatched unrelated donors, probably acounts for the difference in the two studies. Also, was made up of the study group bone marrow transplantation patients with their innate immune deficiencies.…”

Section: Cd25mentioning

confidence: 99%

Long-term follow-up of patients with moderate aplastic anemia and pure red cell aplasia treated with daclizumab

Sloand¹,

Olnes

Weinstein

et al. 2010

Haematologica

View full text Add to dashboard Cite

The online version of this article has a Supplementary Appendix. BackgroundPure red cell aplasia and moderate aplastic anemia are marrow failure states with an immune pathogenesis. Previously, we described short-term improvements in blood counts in two pilot studies treating moderate aplastic anemia (mAA) and pure red cell aplasia (PRCA) patients with daclizumab, a humanized monoclonal antibody to the interleukin-2 receptor; we now report our long-term experience with a larger cohort of patients. Design and MethodsAfter a median follow-up period of 4.8 years, 19 of 45 (42%) evaluable mAA patients and 10 of 26 (38%) patients with PRCA responded by three months and 2 additional m-AA patients responded by six months following administration of the drug. ResultsSeven of 28 (25%) mAA patients achieved long-term packed red blood cell PRBC transfusion independence, and all PRCA responders achieved long-term transfusion PRBC transfusion independence. ConclusionsRed cell transfusion-independence prior to treatment in mAA patients predicted response. The only significant adverse treatment-related events were transient rashes and arthralgias. Daclizumab is safe and effective, and produces lengthy remissions in patients with PRCA and mAA.Key words: interleukin-2 receptors, immunosuppression, T-regulatory cells, marrow failure.Citation: Sloand EM, Olnes MJ, Weinstein B, Wu C, Maciejewski J, Scheinberg P, and Young NS. Long-term follow-up of patients with moderate aplastic anemia and pure red cell aplasia treated with daclizumab. Haematologica. 2010;95:382-387. doi: 10.3324/haematol.2009 This is an open-access paper.Long-term follow-up of patients with moderate aplastic anemia and pure red cell aplasia treated with daclizumab

show abstract

Manifestations and Treatment of Acute Graft‐versus‐Host Disease

Cutler

Antin

2015

Thomas’ Hematopoietic Cell Transplantation

View full text Add to dashboard Cite

Long-term follow-up of patients treated with daclizumab for steroid-refractory acute graft-vs-host disease

Cited by 71 publications

References 21 publications

Daclizumab as useful treatment in refractory acute GVHD: a paediatric experience

Daclizumab as useful treatment in refractory acute GVHD: a paediatric experience

Long-term follow-up of patients with moderate aplastic anemia and pure red cell aplasia treated with daclizumab

Manifestations and Treatment of Acute Graft‐versus‐Host Disease

Contact Info

Product

Resources

About